The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Updated results of a prospective noninterventional study of everolimus after use of 1 VEGFR-TKI.
Lothar Bergmann
Consultant or Advisory Role - Novartis; Pfizer
Honoraria - Novartis
Peter J. Goebell
Consultant or Advisory Role - Novartis
Ulrich Kube
No relevant relationships to disclose
Manfred Kindler
No relevant relationships to disclose
Edwin Herrmann
No relevant relationships to disclose
Jan Janssen
No relevant relationships to disclose
Joerg Schmitz
No relevant relationships to disclose
Steffen Weikert
No relevant relationships to disclose
Susanne Kloss
No relevant relationships to disclose
Gabriel Steiner
No relevant relationships to disclose
Andreas Jakob
Consultant or Advisory Role - Novartis
Michael D. Staehler
Consultant or Advisory Role - Bayer; GlaxoSmithKline; Novartis; Pfizer
Thomas Steiner
Consultant or Advisory Role - Amgen; Bayer; GlaxoSmithKline; Novartis; Pfizer
Friedrich Overkamp
Consultant or Advisory Role - Novartis
Gernot Guderian
Employment or Leadership Position - Novartis
Christian Doehn
Consultant or Advisory Role - GlaxoSmithKline; Novartis